• Dose 3 PCV should forecast for at least 12 months of age and at least 8 weeks as final dose if previous dose is 7-11 months of age
• Td/Tdap booster should be 10 years for accelerated date.
• Update RSV MAB forecasting and evaluation, review RSV vaccine for 24-25 season will become effective on 4/1/2024
• CVX 30 HepB IG manufacturer’s list has been updated to add Grifols Therapeutics
• The issue with HL7 Rejection resulting in deduction from Beyfortus inventory has been resolved.

For more information, see MCIR Release Notes PDF